(STOCKHOLM) -- Researchers are discounting the bone drug Zometa in the fight against breast cancer, according to HealthDay.
A new study published in the New England Journal of Medicine found that Zometa does not prevent the breast cancer from recurring. The study will be presented Sunday at the 2011 European Multidisciplinary Cancer Congress in Stockholm.
Women recovering from breast cancer often suffer from weakened bones. Research previously suggested that bone-strengthening drugs like Zometa helped in keeping the cancer away.
Copyright 2011 ABC News Radio